Russian pharmaceutical company NATIVA announced a strategic agreement concerning cooperation in the manufacture of innovative dispensing solutions for respiratory disease treatment with VARI, a wholly-owned subsidiary of LINDAL Group and one of the leading makers of valves and actuators for pharmaceutical aerosol systems.
Such cooperation includes metered dose inhalers, which require the highest levels of technical and manufacturing expertise. These solutions use carefully engineered valves made to handle active ingredients and optimize delivery of low doses of medication directly inside the bronchial tree.
Both VARI and Nativa anticipate further growth of their business relationship. “Lindal is pleased to have this opportunity to broaden its relationship with Nativa,” said Phil Lever, Group Sales Director for LINDAL Group. “We look forward to future, mutually beneficial strategic projects with this leading pharmaceutical company, which ultimately will benefit healthcare professionals and their patients around the globe.”
According to Alexander Malin, CEO of Nativa, “Our company values are focused on our own R&D development and low batch production, as well as the involvement of the world’s leaders in related technology.
“One of the significant results of long-term partnership between Nativa and the European leader VARI – LINDAL Group was the strategic agreement for technology transfer of drug manufacturing for respiratory diseases treatment in the form of metered aerosol,” he added. “This joint project will allow us to market high-demand drugs for patients and citizens of the Russian Federation, to provide adaptation of the European technology to the Russian environment, as well as to create favorable conditions for release the series of drugs based on our process.”
The LINDAL Group is a worldwide leader in the development and manufacture of valves, actuators and spray caps for aerosol products used in pharmaceutical, cosmetics and food applications, and is renowned for its innovative solutions.
Nativa is a fast-growing Russian pharmaceutical company founded in 2010. Its production facility creates full cycle manufacturing, from active pharmaceutical ingredients (APIs) to drug formulation production. The company develops and produces both generics as well as original drugs. Pulmonology is a key area in company’s business.